Targeting insulin-like growth factor pathways

Some cancer cells depend on the function of specific molecules for their growth, survival, and metastatic potential. Targeting of these critical molecules has arguably been the best therapy for cancer as demonstrated by the success of tamoxifen and trastuzumab in breast cancer. This review will eval...

Descripción completa

Detalles Bibliográficos
Autor principal: Yee, D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361182/
https://www.ncbi.nlm.nih.gov/pubmed/16450000
http://dx.doi.org/10.1038/sj.bjc.6602963
_version_ 1782153153395818496
author Yee, D
author_facet Yee, D
author_sort Yee, D
collection PubMed
description Some cancer cells depend on the function of specific molecules for their growth, survival, and metastatic potential. Targeting of these critical molecules has arguably been the best therapy for cancer as demonstrated by the success of tamoxifen and trastuzumab in breast cancer. This review will evaluate the type I IGF receptor (IGF-IR) as a potential target for cancer therapy. As new drugs come forward targeting this receptor system, several issues will need to be addressed in the early clinical trials using these agents.
format Text
id pubmed-2361182
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23611822009-09-10 Targeting insulin-like growth factor pathways Yee, D Br J Cancer Minireview Some cancer cells depend on the function of specific molecules for their growth, survival, and metastatic potential. Targeting of these critical molecules has arguably been the best therapy for cancer as demonstrated by the success of tamoxifen and trastuzumab in breast cancer. This review will evaluate the type I IGF receptor (IGF-IR) as a potential target for cancer therapy. As new drugs come forward targeting this receptor system, several issues will need to be addressed in the early clinical trials using these agents. Nature Publishing Group 2006-02-27 2006-01-31 /pmc/articles/PMC2361182/ /pubmed/16450000 http://dx.doi.org/10.1038/sj.bjc.6602963 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Minireview
Yee, D
Targeting insulin-like growth factor pathways
title Targeting insulin-like growth factor pathways
title_full Targeting insulin-like growth factor pathways
title_fullStr Targeting insulin-like growth factor pathways
title_full_unstemmed Targeting insulin-like growth factor pathways
title_short Targeting insulin-like growth factor pathways
title_sort targeting insulin-like growth factor pathways
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361182/
https://www.ncbi.nlm.nih.gov/pubmed/16450000
http://dx.doi.org/10.1038/sj.bjc.6602963
work_keys_str_mv AT yeed targetinginsulinlikegrowthfactorpathways

Ejemplares similares